Aradigm Corporation company was founded in 1991 and is based in Hayward, California. Aradigm Corporation, a pharmaceutical company, engages in the development and commercialization of drugs delivered by inhalation for the treatment of respiratory diseases by pulmonologists in the United States. Aradigm company's activities include partnered and self-initiated development programs addressing the treatment of cystic fibrosis, bronchiectasis, pulmonary arterial hypertension, chronic obstructive pulmonary disease (COPD), inhalation anthrax infections, and smoking cessation. Its proprietary product candidates under development include ARD-3100 under phase II clinical trial for the treatment of cystic fibrosis; ARD-3150 under phase II clinical trial for the treatment of bronchiectasis; ARD-1600 under phase I clinical trial for the treatment of tobacco smoking cessation; and ARD-1100, a preclinical product for the treatment of inhalation anthrax indications. Aradigm company's collaborative product candidates comprise ARD-1550, a phase II product and ARD-1500, a preclinical stage product for the treatment of pulmonary arterial hypertension; and ARD-1700, a preclinical stage product for the treatment of asthma and COPD. Aradigm Corporation has a collaboration agreement with CyDex Pharmaceuticals, Inc. for the development and commercialization of products to deliver inhaled corticosteroids, anticholinergics, and beta-2 agonists for the treatment of asthma and COPD.

China Shenghuo Pharmaceutical Holdings, Inc. (Shenghuo) is primarily engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products. Almost all of its products are derived from the medicinal herb Panax notoginseng, also known as Sanqi, Sanchi or Tienchi. Its main product, Xuesaitong Soft Capsules, accounted for more than 87% of its sales for the year ended December 31, 2008. Xuesaitong Soft Capsules are primarily sold in China, but the product is also sold in various developing countries, including Malaysia, Indonesia and Kyrgyzstan. Panax notoginseng saponins (PNS), the active ingredient in Panax notoginseng, is extracted from the plant using high-tech equipment and in accord with Good Manufacturing Practice (GMP) standards.

Galderma Laboratories, L.P., a dermatology company, engages in the research, development, and marketing of dermatology products. Its pharmaceutical and over-the-counter products include Differin, which is used to treat acne; MetroGel, MetroLotion, and MetroCream, to treat rosacea; Clobex lotion, which helps in controlling and treating moderate-to-severe plaque psoriasis; and Cetaphil, a line of cleansers and moisturizers. The company has operations in North America, Western Europe, Latin America, Asia, Australia, and Africa. It offers its services directly, and through sales representatives, as well as through special programs. The company was founded in 1961 as Owen Laboratories and changed its name to Galderma Laboratories, L.P. in 1981. The company is headquartered in Fort Worth, Texas. Galderma Laboratories, L.P. operates as a subsidiary of Galderma SA.

Genzyme Corporation (Genzyme) is a biotechnology company. Genzyme operates in four segments: Genetic Diseases, Cardiometabolic and Renal, Biosurgery and Hematologic Oncology. Genetic Diseases unit develops, manufactures and distributes therapeutic products, with a focus on products to treat patients suffering from genetic diseases and other chronic debilitating diseases, including a family of diseases known as lysosomal storage disorders (LSDs). Cardiometabolic and Renal segment develops, manufactures and distributes products that treat patients suffering from renal diseases, including chronic renal failure and endocrine and cardiovascular diseases. Biosurgery segment develops, manufactures and distributes biotherapeutics and biomaterial-based products, with a focus on products that meet medical needs in the orthopaedics and broader surgical areas. Hematologic Oncology segment develops, manufactures and distributes products for the treatment of cancer.

BG Medicine wants to fill big gaps in diagnostic medicine. The biosciences researcher primarily provides drug research and development services to such top global pharmaceutical makers as Pfizer and AstraZeneca, US government agencies, and to the health care product divisions of companies like Mitsubishi. BG Medicine specializes in developing biomarkers, substances used to detect disease at a molecular level, that enable research into the causes of disease and the effectiveness of drugs used to treat them. Products in the planning and discovery stages include molecular diagnostic tests for heart disease, neurological disorders, and cancer.

Roche Holding (UK) is the holding company for Roche Products Limited and Roche Diagnostics Limited. The two UK subsidiaries develop and manufacture various products and equipment for the diagnosis and treatment of disease. Its pharmaceuticals include Copegus, a hepatitis C therapy; HIV inhibitor Fuzeon; and breast cancer therapy Herceptin. The firm's diagnostics arm makes a variety of consumer and professional tests, including Accu-Chek glucose monitoring systems, CoaguChek blood coagulation tests, and the Amplicor line of DNA disease diagnostics.

Avalon Pharmaceuticals doesn't mind if genes express themselves -- but they should know that anything they express can and will be used against them if they lead to cancer. The biopharmaceutical firm develops cancer therapeutics based on its AvalonRx platform, which identifies compounds that would be best suited to advance in clinical drug development. Lead product AVN944, an inhibitor of hematologic (leukemia, lymphoma, and myeloma) and solid tumor cancers, is an oral drug now in clinical trials. Avalon also has preclinical programs to develop inhibitors through partnerships with other drug companies. The company was acquired by Clinical Data in 2009.

Genmab was founded in 1999. Genmab analyzes genomes in its lab. The biotech company creates and develops human antibodies to treat such conditions as lymphoma and other cancers, as well as autoimmune and inflammatory diseases. It has assembled a portfolio of products under its HuMax brand that are in different stages of development, ranging from pre-clinical to late-stage trials. In addition to developing its HuMax products, Genmab is working to create products for conditions such as infectious diseases and vascular conditions. The company has licensing and development partnerships with several international pharmaceutical and biotech companies including GlaxoSmithKline, Amgen, Medarex, and Roche.

Elite Pharmaceuticals, Inc. (Elite) is a specialty pharmaceutical company principally engaged in the development and manufacture of oral, controlled-release products. The Company’s activity includes improving off-patent drug products for life cycle management and developing generic versions of controlled-release drug products. Its technology is applicable to develop delayed, sustained or targeted-release pellets, capsules, tablets, granules and powders. As of March 31, 2009, the Company had two products, Lodrane 24 and Lodrane 24D, being sold commercially, and a pipeline of five additional drug candidates under active development in the therapeutic areas that include pain management, allergy and infection. Of the products under development, ELI-216, a once-a-day, abuse-deterrent oxycodone product, and ELI-154, a once-a-day oxycodone product, are in clinical trials, and Elite has completed pilot studies on two of its other generic product candidates.

Lectus Therapeutics Limited is a UK-based pharmaceutical company. Its mission is to build a development pipeline containing first-in-class ion channel therapeutics identified through the use of its proprietary proteomics technology for pain management and the treatment of urinary bladder disorders.Lectus, which began operations in the summer of 2003, exploits the power of its proprietary functional proteomics platform, LEPTICS® (Leveraged Enabling Proteomics Technology for Ion Channel Screening), and builds on its knowledge of ion channels and protein-protein interactions, to identify and develop next-generation ion channel modulators that offer desirable clinical profiles with commensurate economic advantages.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.